WSMS199

WSMS199 Oct 22, 2024

Poised to disrupt mental health treatment Cybin is on the verge of a revolution unlike any treatment the world has ever seen in depression. Phase 3 trails/data will bring many catalysts for the future, into the unknown where no one has gone legally before..

WSMS199 Oct 20, 2024

Projected revenues for 2026 are 26,000% increase. June 2024 revenue Growth (YoY) 8630.55% After a negative growth 2023. With a wide range of drugs and applications the future seems promising.

WSMS199 Oct 20, 2024

Encouraging preliminary progress on their phase 2 schizophrenia drug has pushed the one year target to $40 currently at $5.65. Last breakout from this range in Jan 2021 resulted in a 350% surge in one week. There are few resistances ahead for consolidation at $8, 10, 14, 20.

WSMS199 Oct 20, 2024

Above all moving averages besides 200 weekly for now.. primed and ready for a strong move. Impressive Revenue growth, major cash flow increase, announced a share buy back with new CFO last week. break of 2.10 game on

WSMS199 Oct 17, 2024

Speculative play here gaining traction. Predicted to have good revenues q4 q1 higher risk higher reward holding spot from .1

WSMS199 Oct 8, 2024

Cancelations could be decent, DOWNGRADED to UNDERWRIGHT PT $550. not going long here if you know what im sayin